Skip to main content
NewslettersWatchlist
The Globe and Mail Trade Off — test investment strategies with a $100,000 virtual portfolio and see how your portfolio measures up against the crowd. Play Now!

Portage Biotech Inc Ord(PRTG-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low6.80
Day High9.43
Open:7.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Portage Biotech Inc Ord

Select a category then submit the form to load news
Tipranks
AlphaTON Capital Corp Enters ATM Agreement with Chardan Capital Markets
Tipranks
AlphaTON Capital Corp Embraces Digital Asset Strategy with TON Token Focus
Tipranks
Portage Biotech Reports Improved Fiscal Year Results
Tipranks
Portage Biotech Reports Reduced Losses Amid Strategic Operational Shifts
Baystreet
Portage Down on Announcing Alternatives
Globe Newswire
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Globe Newswire
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Globe Newswire
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Globe Newswire
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
Globe Newswire
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
Globe Newswire
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Globe Newswire
Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
Globe Newswire
Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
Globe Newswire
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Profile

Portage Biotech Inc. is a clinical stage immuno-oncology company focused on overcoming immune resistance. The company source, nurture and develop therapies for a variety of cancers. Its drug development pipeline portfolio encompasses products or technologies with established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.